W.G. Shaheen & Associates DBA Whitney & Co trimmed its position in Aetna Inc. (NYSE:AET) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,310 shares of the company’s stock after selling 930 shares during the quarter. Aetna makes up approximately 3.1% of W.G. Shaheen & Associates DBA Whitney & Co’s portfolio, making the stock its 2nd biggest holding. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Aetna were worth $9,461,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in AET. BlackRock Inc. raised its stake in Aetna by 3,374.9% in the first quarter. BlackRock Inc. now owns 30,712,219 shares of the company’s stock valued at $3,917,344,000 after purchasing an additional 29,828,390 shares in the last quarter. Vanguard Group Inc. raised its stake in Aetna by 3.8% in the first quarter. Vanguard Group Inc. now owns 23,117,526 shares of the company’s stock valued at $2,948,640,000 after purchasing an additional 838,578 shares in the last quarter. FMR LLC raised its stake in Aetna by 73.8% in the second quarter. FMR LLC now owns 13,736,800 shares of the company’s stock valued at $2,085,659,000 after purchasing an additional 5,833,567 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Aetna by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 3,962,514 shares of the company’s stock valued at $505,399,000 after purchasing an additional 21,953 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Aetna by 26.0% in the first quarter. AQR Capital Management LLC now owns 3,639,077 shares of the company’s stock valued at $464,165,000 after purchasing an additional 751,166 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Aetna Inc. (NYSE AET) traded down 1.359% on Friday, hitting $151.305. 1,056,211 shares of the stock traded hands. The firm has a market cap of $50.25 billion, a PE ratio of 33.586 and a beta of 0.53. The firm has a 50 day moving average price of $157.50 and a 200 day moving average price of $145.70. Aetna Inc. has a 52-week low of $104.59 and a 52-week high of $164.52.
Aetna (NYSE:AET) last released its quarterly earnings results on Thursday, August 3rd. The company reported $3.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.34 by $1.08. Aetna had a return on equity of 20.52% and a net margin of 2.52%. The company had revenue of $15.52 billion for the quarter, compared to analyst estimates of $15.34 billion. During the same quarter in the prior year, the firm posted $2.21 EPS. Aetna’s quarterly revenue was down 2.7% compared to the same quarter last year. On average, equities analysts forecast that Aetna Inc. will post $9.55 EPS for the current year.
AET has been the topic of a number of recent analyst reports. Royal Bank Of Canada raised their target price on shares of Aetna from $147.00 to $162.00 and gave the company an “outperform” rating in a research note on Friday, June 9th. BidaskClub downgraded shares of Aetna from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Deutsche Bank AG raised their target price on shares of Aetna from $157.00 to $163.00 and gave the company a “hold” rating in a research note on Monday, August 7th. Morgan Stanley initiated coverage on shares of Aetna in a research note on Tuesday, June 6th. They issued an “overweight” rating and a $162.00 target price on the stock. Finally, Argus reaffirmed a “buy” rating and issued a $165.00 target price (up from $145.00) on shares of Aetna in a research note on Tuesday, May 30th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $159.04.
COPYRIGHT VIOLATION WARNING: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/09/22/aetna-inc-aet-is-w-g-shaheen-associates-dba-whitney-cos-2nd-largest-position.html.
In related news, President Karen S. Lynch sold 15,271 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the sale, the president now owns 64,261 shares in the company, valued at approximately $10,404,498.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Margaret M. Mccarthy sold 10,288 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $162.85, for a total value of $1,675,400.80. Following the sale, the executive vice president now owns 33,563 shares in the company, valued at approximately $5,465,734.55. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Receive News & Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related companies with MarketBeat.com's FREE daily email newsletter.